

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: EGF Theramed Health Corp. (the "Issuer").

Trading Symbol: TMED

Number of Outstanding Listed Securities: 41,073,615

Date: July 8, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On June 2, the Company announced that it has entered into a definitive share purchase agreement, dated May 31, 2021, pursuant to which it will acquire all of the issued and outstanding share capital of Seedadelic Health Services Corp. More information on Seedadelic can be found in the news release dated June 2, 2021.

On June 3, 2021, the Company announced that it has arranged a non-brokered private placement for up to 1,666,667 units at a price of 12 cents per unit for gross proceeds of \$200,000.04. Each unit will comprise of one common share of the company and one-half of one common share purchase warrant of the company. Each full warrant will be exercisable into a common share of the company for a period of 12 months at an exercise price of 20 cents during the 12 months. The proceeds of the private placement will be used for general working capital.

On June 23, 2021, the Company closed its previously announced non-broker private placement for 1,666,667 units at a price of 12 cents per unit for gross proceeds of \$200,000.04. Of the proceeds, \$50,000.04 will be used for general working capital while the remaining \$150,000 will be used to retain Awareness Consulting Network LLC for increasing investor awareness for the Company.

On June 25, 2021, the Company announced that its subsidiary joint venture Pharmadelic Labs Inc. has signed a laboratory service agreement with Numinus Wellness Inc. Details on Pharmadelic Labs Inc. and Numinus Wellness Inc. can be found in the news release dated June 25, 2021.

On June 28, 2021, the Company announced that it has arranged a non-brokered private placement for up to 3,333,334 units at a price of 12 cents per unit for gross proceeds of \$400,000.08.

Each unit will comprise one common share of the company and one-half of one common share purchase warrant of the company. Each full warrant will be exercisable into a common share of the company for a period of 12 months at an exercise price of 20 cents during the 12 months.

Of the proceeds, \$200,000.08 will be used for general working capital while the remaining \$200,000 will be used for investor awareness programs for the company.

2. Provide a general overview and discussion of the activities of management.

The Issuer has no new activities from management for the month of June 20201

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer did not develop any new products or services during the month of June 2021.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

The Issuer did not discontinue any products or services during the month of June 2021.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

The Issuer did not have expiry or termination of any contracts or agreements during the month of June 2021.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On June 9, 2021, the company acquired Seedadelic Health Services Corp. pursuant to its previously announced definitive share purchase agreement, dated May 31, 2021.

8. Describe the acquisition of new customers or loss of customers.

The Issuer did not acquire or lose any customers during the month of June 2021.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Issuer did not have any new developments during the month of June 2021.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Issuer did not hire, terminate or lay-off any employees during the month of June 2021.

11. Report on any labour disputes and resolutions of those disputes if applicable.

The Issuer had no labour disputes as of June 2021.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Issuer is not a party to any legal proceedings.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Issuer did not incur or repay any indebtedness during June 2021.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

The Issuer did not receive/make any loans from/to Related Persons during June 2021.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in the month of June 2021.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The Issuer is not aware of any trends, uncertainties, demands, commitments or events which are reasonably likely to have a material effect upon its revenues, income from continuing operations, profitability, liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 8, 2021.

Usama Chaudhry

Name of Director or Senior Officer

/s/ Usama Chaudhry

Signature

CFO

Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		Ended	YY/MM/D
EGF Theramed Health Corp.		June 2021	2021-07-08
Issuer Address			
Suite 1600 – 609 Granville Street			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC, V7Y 1C3			(604) 331-8505
Contact Name		Contact Position	Contact Telephone No.
Doug McFaul		Administration	(604) 331-8505
Contact Email Address		Web Site Address	
dmcfaul@emprisecapital.com		www.theramedhealthcorp.com	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015